Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Expanded_access × lifileucel × 1 year × Clear all

Status

Sponsor Class

Study Type

Interventional 10 Expanded_access 1

Sponsor

Cancer Type

Conditions

Interventions

talquetamab 2 ruxolitinib 2 Suspensions 2 Powders 2 Gemcitabine 2 3-Iodobenzylguanidine 2 zolbetuximab 1 zenocutuzumab 1 zanidatamab 1 venetoclax 1 ulixertinib 1 tucatinib 1 trametinib 1 tisagenlecleucel 1 tipifarnib 1 telisotuzumab vedotin 1 taletrectinib 1 talazoparib 1 sotorasib 1 selinexor 1 ribociclib 1 revumenib 1 pembrolizumab 1 patritumab deruxtecan 1 omburtamab I-131 1 omaveloxolone 1 nirogacestat 1 niraparib 1 mirdametinib 1 mifamurtide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05398640 2025-06-17

Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release

Iovance Biotherapeutics, Inc.

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡